Agio Pharmaceuticals Limited Bromhexine Export Data — India (DGFT 2022–2026)

Name: Agio Pharmaceuticals Limited Bromhexine Export Records India — #5 Exporter, 41 Shipments, $849.1K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus
Published: 2026-05-01T00:00:00Z
License: https://transdatanexus.com/terms-and-conditions

Suresh Sormare

Bromhexine

India Pharmaceutical Trade Intelligence

$16.3M288 Suppliers109 CountriesHS 30049099

ExportsIndia → ANGOLA19.0%India → AUSTRALIA9.3%

#1 Supplier: UMAVIDA PHARMA #1 Buyer: PRINCE FARMA,

Agio Pharmaceuticals Limited — Bromhexine Exporter #5 | $849.1K Trade Value | TransData Nexus | TransData Nexus

Agio Pharmaceuticals Limited — Bromhexine Exporter Profile

Indian Pharmaceutical Exporter · #5 for Bromhexine · $849.1K export value · DGFT Verified

Agio Pharmaceuticals Limited is the #5 Indian exporter of Bromhexine with $849.1K in export value and 41 verified shipments. Agio Pharmaceuticals Limited holds a 5.2% market share in Bromhexine exports across 4 countries. The company exports 15 pharmaceutical products worth $11.9M across 8 therapeutic categories.

Agio Pharmaceuticals Limited — Bromhexine Export Profile: Buyers & Destinations

Agio Pharmaceuticals Limited Bromhexine export treemap — buyers and destination countries | TransData Nexus

Where Does Agio Pharmaceuticals Limited Export Bromhexine?

Country	Value	Shipments	Share
RUSSIA	$798.6K	34	91.3%
UZBEKISTAN	$27.8K	2	3.2%
KYRGHYSTAN	$27.7K	4	3.2%
KYRGYZSTAN	$16.9K	1	1.9%
KENYA	$3.2K	1

Who Are the Top Buyers of Bromhexine from Agio Pharmaceuticals Limited?

Buyer	Country	Value	Orders
AGIO RUS LLC	RUSSIA	$798.6K	34
OSOO ELYAI	KYRGHYSTAN	$27.7K	4
AMRITA PHARMA LLC	UZBEKISTAN	$18.3K	1
NEMAN-FARM LLC	KYRGYZSTAN	$16.9K	1
AGIO HEALTHCARE INTERNATIONAL LLC	UZBEKISTAN	$9.5K	1
TO THE ORDER OF SYNERMED	KENYA	$3.2K	1

Agio Pharmaceuticals Limited supplies Bromhexine to 6 buyers globally. The largest buyer is AGIO RUS LLC (RUSSIA), followed by OSOO ELYAI (KYRGHYSTAN) and AMRITA PHARMA LLC (UZBEKISTAN). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.

What Bromhexine Formulations Does Agio Pharmaceuticals Limited Export?

Product Description / Formulation	Value	Shipments
KOFASMA SYRUP 200 ML (BROMHEXINE + GUAIFENESIN + SALBUTAMOL SYRUP)	$546.4K	23
KOFASMA SYRUP 200 ML BROMHEXINE + GUAIFENESIN + SALBUTAMOL SYRUP	$135.8K	4
KOFASMA SYRUP 100 ML (BROMHEXINE + GUAIFENESIN + SALBUTAMOL SYRUP)	$59.6K	4
KOFASMA SYRUP 200 ML (BROMHEXINE + GUAIF	$39.2K	1
KOFASMA SYRUP (SALBUTAMOL, BROMHEXINE HY	$27.7K	4
KOFASMA SYRUP (SALBUTAMOL,BROMHEXINE HYD	$18.3K	1
KOFASMA SYRUP (SALBUTAMOL, BROMHEXINE HYDROCHLORIDE & GUAIFENESIN SYRUP (2MG+4MG+100MG))	$16.9K	1
KOFASMA SYRUP 200 ML(BROMHEXINE+GUAIFENE	$11.9K	1
KOFASMA SYRUP (SALBUTAMOL + BROMHEXINE+GUAIFENESIN+MENTHOL SYRUP)	$9.5K	1
KOFASMA SYRUP 200ML (BROMHEXINE + GUAIFE	$5.8K	1

Agio Pharmaceuticals Limited exports 11 distinct Bromhexine formulations including tablets, capsules, syrups, and combination drugs. The top formulation is KOFASMA SYRUP 200 ML (BROMHEXINE + GUAIFENESIN + SALBUTAMOL with 23 shipments worth $546.4K.

How Does Agio Pharmaceuticals Limited Compare to Nearest Bromhexine Exporters?

Exporters ranked immediately above and below #5 by export value

#	Supplier	Export Value	Shipments	Countries	Avg/Shipment
2	EMCURE PHARMACEUTICALS LIMITED	$2.1M	119	14	$18.0K
4	J B CHEMICALS AND PHARMACEUTICALS LIMITED	$907.7K	48	3	$18.9K
5	AGIO PHARMACEUTICALS LIMITED ★	$849.1K	41	4	$20.7K
6	LINCOLN PHARMACEUTICALS LTD	$600.0K	12	5	$50.0K
7	GLENMARK PHARMACEUTICALS LIMITED	$595.1K	31	7	$19.2K

Agio Pharmaceuticals Limited ranks #5 among 288 Indian Bromhexine exporters. Average shipment value of $20.7K compared to the market average of $35.7K. The closest competitors by value are EMCURE PHARMACEUTICALS LIMITED and J B CHEMICALS AND PHARMACEUTICALS LIMITED.

Which Indian Ports Ship Bromhexine Exports?

Port	Shipments	% Share
NHAVA SHEVA SEA (INNSA1)	303	15.6%
JNPT	169	8.7%
JNPT/ NHAVA SHEVA SEA	164	8.4%
SAHAR AIR CARGO ACC (INBOM4)	157	8.1%
AHEMDABAD ICD	74	3.8%
SAHAR AIR	73	3.8%
AHEMDABAD AIR ACC (INAMD4)	72	3.7%
AHEMDABAD ICD (INSBI6)	59	3.0%

Geopolitical & Trade Policy Impact on Agio Pharmaceuticals Limited's Bromhexine Exports

Recent geopolitical developments have introduced complexities into the pharmaceutical export landscape. The Israel-Iran conflict has led to disruptions in Red Sea shipping routes, causing increased freight charges and potential losses for Indian exporters. According to Pharmaceutical Commerce, maritime carriers' booking suspensions and diversions around the Cape of Good Hope are elongating lead times and pressurizing Suez-linked lanes, disproportionately impacting time-sensitive pharmaceutical replenishment cycles. This situation poses challenges for Agio Pharmaceuticals, particularly in maintaining timely deliveries to key markets.

In the United States, recent tariff implementations have affected a significant portion of Indian exports. The Federation of Indian Export Organisations highlighted that the latest U.S. tariffs impact nearly 55% of India's outbound shipments to America, placing Indian exporters at a competitive disadvantage. For Agio, which relies on the U.S. market, these tariffs could necessitate strategic adjustments to pricing and supply chain logistics.

The European Union's stringent regulatory changes, including the Falsified Medicines Directive, demand enhanced compliance measures from exporters. Agio's ability to adapt to these evolving standards will be crucial in sustaining its market presence in the EU.

Agio Pharmaceuticals Limited — Regulatory Compliance & Quality Standards

The global pharmaceutical industry is witnessing heightened regulatory scrutiny, with agencies like the U.S. FDA increasing inspections of manufacturing facilities. India, hosting over 600 US FDA-approved sites, faces challenges in maintaining compliance. The US FDA conducted more than 200 inspections in 2023, with plans to increase this number in 2024. For Agio Pharmaceuticals, ensuring adherence to Good Manufacturing Practices (GMP) and other quality standards is imperative to avoid potential export bans or reputational damage.

Additionally, the prevalence of counterfeit drugs has raised concerns about India's reputation as a reliable supplier. Agio must implement robust quality control systems and transparent governance to navigate this landscape effectively.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Product Matching: Bromhexine shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
2.Supplier Identification: Agio Pharmaceuticals Limited matched across shipments using name normalization, accounting for company name formatting variations.
3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
4.Verified Records: This page is backed by 42 individual customs records matching Agio Pharmaceuticals Limited exporting Bromhexine, covering 11 formulations to 5 countries via 6 buyers.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

Global Coverage

Exports to 109+ countries, 530+ buyers

Expert-Reviewed

Analyzed by pharmaceutical trade specialists

Bromhexine

Bromhexine

Agio Pharmaceuticals Limited — Bromhexine Exporter Profile

Agio Pharmaceuticals Limited — Bromhexine Export Profile: Buyers & Destinations

Where Does Agio Pharmaceuticals Limited Export Bromhexine?

Who Are the Top Buyers of Bromhexine from Agio Pharmaceuticals Limited?

What Is India's Total Bromhexine Export Value and How Much Does Agio Pharmaceuticals Limited Contribute?

What Is the Average Shipment Value for Agio Pharmaceuticals Limited's Bromhexine Exports?

How Does Agio Pharmaceuticals Limited Compare to Other Indian Bromhexine Exporters?

What Bromhexine Formulations Does Agio Pharmaceuticals Limited Export?

How Does Agio Pharmaceuticals Limited Compare to Nearest Bromhexine Exporters?

Which Indian Ports Ship Bromhexine Exports?

What Other Respiratory & OTC Products Does Agio Pharmaceuticals Limited Export?

Geopolitical & Trade Policy Impact on Agio Pharmaceuticals Limited's Bromhexine Exports

Agio Pharmaceuticals Limited — Regulatory Compliance & Quality Standards

About Agio Pharmaceuticals Limited

Market Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Get Bromhexine Export Data from Agio Pharmaceuticals Limited

Bromhexine Stats

Company Overview

Top Products by Agio Pharmaceuticals Limited

Related Analysis

Need Detailed Export Data?

Data Source